Price List - Wezlana - Targeted Immunomodulatory Biologics - IL-23.xlsx
XLSX spreadsheet 52 KB Posted
- Solicitation number
- HT9402-25-Q-9103
- Issued by
-
Defense Health Agency
About this file
This is a pricing template spreadsheet for the Department of Defense Pharmacy & Therapeutics (P&T) Committee meeting in February 2025, specifically for Targeted Immunomodulatory Biologics in the Interleukin-23 (IL-23) subclass. The template allows manufacturers to submit pricing quotes for both the Uniform Formulary Blanket Purchase Agreement (UF BPA) and Additional Discount Program (ADP) by January 16, 2025.
The template includes sections for up to 10 newly approved drugs, with pricing scenarios for different formulary categories including Uniform Formulary Before Step Therapy, Uniform Formulary After Step Therapy, and Non-Formulary After Step Therapy. For each drug, manufacturers must provide NDC numbers, drug names, strengths, dosage forms, package sizes, and pricing information including Federal Ceiling Prices (FCP), non-FAMP prices, and WAC discounts. The document specifies that prior authorization requirements may apply and that the P&T Committee will consider removing step therapy preferences for certain indications like psoriasis and IBD. All quoted discount percentages must remain static during the agreement period.
View the file
Other files
Show all 15
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the February 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 |
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.
Biosimilar Step Therapy Addendum: Since biosimilars are equivalent to the reference product, no grandfathering will apply. No Grandfathering: a prior authorization may process require new and current patients to complete an adequate trial of the step-preferred biosimilar(s) before a non-step-preferred biosimilar is provided to the patient at any MTF, Retail, or Mail point of service.
| • | P&T will consider removing the TIBS class step preference (i.e., adalimumab) for select indications (e.g., psoriasis, IBD). |
| • | Agents with RFQ not submitted or selected may be designated non-step preferred. |
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 251TB23G1UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 251TB23G1UFAS1M | Uniform Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 251TB23G1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 251TB23G1UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 251TB23G1UFAS1M | Uniform Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 251TB23G1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 251TB23G1UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 251TB23G1UFAS1M | Uniform Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 251TB23G1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 251TB23G1UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 251TB23G1UFAS1M | Uniform Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 251TB23G1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 251TB23G1UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 251TB23G1UFAS1M | Uniform Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 251TB23G1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 251TB23G1UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 251TB23G1UFAS1M | Uniform Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 251TB23G1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 251TB23G1UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 251TB23G1UFAS1M | Uniform Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 251TB23G1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 251TB23G1UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 251TB23G1UFAS1M | Uniform Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 251TB23G1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 251TB23G1UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 251TB23G1UFAS1M | Uniform Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 251TB23G1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 251TB23G1UFBS1 | Uniform Formulary | |||
| Before Step Therapy | 1 | NO QUOTE | |||
| 251TB23G1UFAS1M | Uniform Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 251TB23G1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Appendix for the February 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 |
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.
Biosimilar Step Therapy Addendum: Since biosimilars are equivalent to the reference product, no grandfathering will apply. No Grandfathering: a prior authorization process may require new and current patients to complete an adequate trial of the step-preferred biosimilar(s) before a non-step-preferred biosimilar is provided to the patient at any MTF, Retail, or Mail point of service.
| • | P&T will consider removing the TIBS class step preference (i.e., adalimumab) for select indications (e.g., psoriasis, IBD). |
| • | Agents with RFQ not submitted or selected may be designated non-step preferred. |
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (WAC Discount)
| UF ADP Appendix for the February 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 |
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.
Biosimilar Step Therapy Addendum: Since biosimilars are equivalent to the reference product, no grandfathering will apply. No Grandfathering: a prior authorization process may require new and current patients to complete an adequate trial of the step-preferred biosimilar(s) before a non-step-preferred biosimilar is provided to the patient at any MTF, Retail, or Mail point of service.
| • | P&T will consider removing the TIBS class step preference (i.e., adalimumab) for select indications (e.g., psoriasis, IBD). |
| • | Agents with RFQ not submitted or selected may be designated non-step preferred. |
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | INTERLEUKIN-23 (IL-23) | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 251TB23G1T2BS1 | Tier 2 | |||
| Before Step Therapy | 1 | ||||
| 251TB23G1T2AS1M | Tier 2 | ||||
| After Step Therapy | 1 or more | ||||
| 251TB23G1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .